Approximately one third of patients with a CDH1 pathogenic variant will never develop symptomatic cancer and therefore a careful watch and wait strategy is a reasonable option in some individuals especially given the profound impact of a total gastrectomy on the quality of life [16, 17]. Here, CDH1 is linked to cancer.